Showing 6221-6230 of 19384 results for "".
Are You in a Groove or in a Rut?
https://reachmd.com/programs/clinicians-roundtable/are-you-in-a-groove-or-in-a-rut/1216/Join Dr. Linda Clever, founder of RENEW, a not-for-profit aimed at helping people maintain and regain enthusiasm help you identify and improve your own psyche in your medical practice.The Challenging Demands Faced by the Neurosurgeon
https://reachmd.com/programs/clinicians-roundtable/the-challenging-demands-faced-by-the-neurosurgeon/1120/Dr. Katrina Firlik, author of "Another Day in the Frontal Lobe: a Brain Surgeon Exposes Life on the Inside" discusses the practice of neurosurgery.Defining Chronic Ocular Surface Pain: Causes, Clues, and Complexity
https://reachmd.com/programs/eye-on-ocular-health/defining-chronic-ocular-surface-pain-causes-clues-and-complexity/37273/Chronic ocular surface pain (COSP) is a multifaceted condition often described by patients as dryness, burning, or grittiness. Despite its prevalence, it frequently presents in relationship to other diseases, which makes understanding these connections and figuring out what exactly to target essentiSexuality After Cancer
https://reachmd.com/programs/clinicians-roundtable/sexuality-after-cancer/756/Join Dr. Kydd as she discusses intimacy and sexuality after surviving cancer.MS Masters Toolbox: Cramps, Spasms, and Spasticity
https://reachmd.com/programs/practical-neurology/cramps-spasms-and-spasticity/31200/In this series, Vito Arena, MD and Ilya Kister, MD from the New York University School of Medicine Comprehensive MS Care Center discuss tools for managing multiple sclerosis symptoms. These gems are guided by research and intended to improve quality of life for people with MS. Episode 4 provides tooATTRibute-CM Findings on Acoramidis and Cumulative CV Events
https://reachmd.com/programs/on-the-frontlines-of-attr-cm/attribute-cm-acoramidis-cv-events/49036/An exploratory analysis of the ATTRibute-CM trial revealed that acoramidis meaningfully reduces cumulative cardiovascular events as early as one month into treatment. Learn more about these findings and their implications for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) as Ryan QuiglHope or Hype -- The High Cost of Medical Advances
https://reachmd.com/programs/clinicians-roundtable/hope-or-hype-the-high-cost-of-medical-advances/1195/Dr. Michael Greenberg welcomes Dr. Richard Deyo, Professor of Medicine and Health Services at the University of Washington, Seattle, WA, as he discusses his book, Hope or Hype, and how physicians are seduced by the bottom line medical industry.Redefining First-Line Therapy in mCSPC: Applying Evidence in Practice
https://reachmd.com/programs/project-oncology/redefining-first-line-therapy-in-mcspc-applying-evidence-in-practice/49229/Treatment for metastatic castration-sensitive prostate cancer (mCSPC) has evolved significantly, moving beyond androgen deprivation therapy alone to more proactive combination approaches that can improve survival. Findings from key trials like CHAARTED, LATITUDE, and ARASENS have helped shape this sPatient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
https://reachmd.com/programs/on-the-frontlines-of-attr-cm/attr-cm-patient-voices/49033/What do patients with transthyretin amyloid cardiomyopathy (ATTR-CM) really experience during their diagnostic and care journeys? Find out as Dr. Quan Bui joins Ryan Quigley to share findings from in-depth patient interviews spotlighting delayed diagnoses, disparities in access, and the complexAssessing the Role of Metabolic Factors in Psoriasis Management
https://reachmd.com/programs/Audioabstracts/metabolic-factors-psoriasis-management/39678/Emerging research highlights a stronger-than-expected connection between body composition and psoriasis outcome, with a large real-world study examining how body mass index, basal metabolic rate, body surface area, and body weight impact both disease severity and biologic treatment response. Tune in